PMC:7652766 / 117928-119920 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T169","span":{"begin":708,"end":727},"obj":"Phenotype"}],"attributes":[{"id":"A169","pred":"hp_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/HP_0002878"}],"text":"Conclusion\nIn conclusion, this collection of works suggests that the genomic changes of SARS-CoV-2 are responsible for its higher transmissibility rate and severity in relation to other hCoVs. Furthermore, the process of tropism and invasion of the virus is favored by its capacity of high-affinity bonding to the human ACE2 receptor. Cytokines have a direct role in the immunopathogenesis of COVID-19 by inducing the hyper inflammation and lung injury peculiar to the disease. Benefits of IFN-mediated response seem to occur only during early infection, and the failed control of its production over time might be related to the worsening of the disease. Monocytes and macrophages have an important role in respiratory failure during COVID-19; several studies have reported that these cells migrate to the lungs, producing pro-inflammatory cytokines, like IL-6, and inducing epithelial damage. Controversially, at later stages, COVID-19 patients present an impaired immune response due to exhausted phenotype and lower effector T cells, CD8+ T lymphocytes, and NK cells, culminating in antiviral immunity loss. Theoretically, the production of specific antibodies against SARS-CoV-2 by the immune system should be able to combat the virus and reduce viral load, but in critically ill patients, it does not seem to occur effectively, contributing to the severity of the disease. Unfortunately, no effective vaccines or therapeutic antiviral agents have been approved for the treatment of COVID-19 so far, but immunotherapy and some repositioned drugs originally used to treat inflammatory and coagulation disorders and viral and parasitic infections are ongoing clinical trials. This is a unique moment in science and humanity, with some mismatched information, as well as novel, important discoveries being made every day, therefore, all information must be interpreted carefully. Our review encompassed the most relevant articles in the area seeking to disseminate good-quality information."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T582","span":{"begin":0,"end":10},"obj":"Sentence"},{"id":"T583","span":{"begin":11,"end":192},"obj":"Sentence"},{"id":"T584","span":{"begin":193,"end":334},"obj":"Sentence"},{"id":"T585","span":{"begin":335,"end":477},"obj":"Sentence"},{"id":"T586","span":{"begin":478,"end":655},"obj":"Sentence"},{"id":"T587","span":{"begin":656,"end":894},"obj":"Sentence"},{"id":"T588","span":{"begin":895,"end":1111},"obj":"Sentence"},{"id":"T589","span":{"begin":1112,"end":1378},"obj":"Sentence"},{"id":"T590","span":{"begin":1379,"end":1678},"obj":"Sentence"},{"id":"T591","span":{"begin":1679,"end":1881},"obj":"Sentence"},{"id":"T592","span":{"begin":1882,"end":1992},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Conclusion\nIn conclusion, this collection of works suggests that the genomic changes of SARS-CoV-2 are responsible for its higher transmissibility rate and severity in relation to other hCoVs. Furthermore, the process of tropism and invasion of the virus is favored by its capacity of high-affinity bonding to the human ACE2 receptor. Cytokines have a direct role in the immunopathogenesis of COVID-19 by inducing the hyper inflammation and lung injury peculiar to the disease. Benefits of IFN-mediated response seem to occur only during early infection, and the failed control of its production over time might be related to the worsening of the disease. Monocytes and macrophages have an important role in respiratory failure during COVID-19; several studies have reported that these cells migrate to the lungs, producing pro-inflammatory cytokines, like IL-6, and inducing epithelial damage. Controversially, at later stages, COVID-19 patients present an impaired immune response due to exhausted phenotype and lower effector T cells, CD8+ T lymphocytes, and NK cells, culminating in antiviral immunity loss. Theoretically, the production of specific antibodies against SARS-CoV-2 by the immune system should be able to combat the virus and reduce viral load, but in critically ill patients, it does not seem to occur effectively, contributing to the severity of the disease. Unfortunately, no effective vaccines or therapeutic antiviral agents have been approved for the treatment of COVID-19 so far, but immunotherapy and some repositioned drugs originally used to treat inflammatory and coagulation disorders and viral and parasitic infections are ongoing clinical trials. This is a unique moment in science and humanity, with some mismatched information, as well as novel, important discoveries being made every day, therefore, all information must be interpreted carefully. Our review encompassed the most relevant articles in the area seeking to disseminate good-quality information."}

LitCovid-PubTator

PMC:7652766 / 117928-119920 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-HP

LitCovid-sentences

LitCovid-PubTator

PMC:7652766 / 117928-119920 JSON TXT